Concord Biotech Ltd Gains 11.13%: 5 Key Factors Driving the Weekly Surge

Monday, 23 February 2026: Fresh 52-Week Low Amid Bearish Technicals

Concord Biotech’s week began with a decline to a 52-week low of Rs.1,090.85, reflecting ongoing financial pressures and deteriorating technical momentum. The stock closed marginally down at Rs.1,099.10, a 0.01% decrease, underperforming the Sensex which gained 0.39%. Key technical indicators such as MACD and moving averages signalled a bearish trend, with the stock trading below all major averages. The company’s recent quarterly results showed a 15.9% drop in profit before tax and a 17.4% decline in profit after tax, contributing to negative sentiment. MarketsMOJO downgraded the stock’s Mojo Grade to Sell, reflecting these challenges.

Tuesday, 24 February 2026: Continued Downtrend and Strong Sell Downgrade

The downtrend intensified as Concord Biotech’s share price fell further to Rs.1,078.10, marking another 52-week low and a 1.91% decline on the day. The stock underperformed its sector by 1.68% and the Sensex which dropped 0.78%. MarketsMOJO downgraded the stock’s rating from Sell to Strong Sell, citing weak financials and bearish technicals. Operating profit growth remained negative at -0.34% annualised over five years, while valuation metrics showed a high price-to-book ratio of 6.3 despite the price fall. The stock’s technical indicators remained firmly bearish, with no immediate signs of reversal.

Midweek Reversal: Wednesday, 25 February 2026 – Intraday Low Followed by Strong Rally

After four consecutive days of decline, Concord Biotech hit a new 52-week low of Rs.1,056.75 early in the session but staged a remarkable intraday recovery, surging 8.15% to an intraday high of Rs.1,145. The stock closed at Rs.1,218.85, outperforming the Sensex’s 0.41% gain and the Pharmaceuticals & Biotechnology sector by 4.84%. This rally was accompanied by heavy trading volumes, with over 1.49 million shares changing hands, making it one of the most actively traded stocks by value. Despite the strong bounce, the stock remained below its longer-term moving averages, indicating that the broader downtrend was not yet broken. The Mojo Score remained at 28.0 with a Strong Sell rating, reflecting ongoing fundamental concerns.

Thursday, 26 February 2026: High-Value Trading Amid Mixed Signals

Concord Biotech remained a focus of market activity on 26 February, with traded volume exceeding 1.59 million shares and a turnover of nearly ₹195.4 crores. Despite this liquidity, the stock closed slightly down at Rs.1,218.85, a 0.80% decline, underperforming the sector’s 1.12% gain and the Sensex’s 0.24% rise. Technical indicators showed the stock trading above its 5-day and 20-day moving averages but still below longer-term averages, reflecting a mixed technical picture. Notably, delivery volumes surged by nearly 3,000% compared to the five-day average, signalling strong institutional participation. The Mojo Grade remained at Strong Sell, underscoring persistent fundamental concerns despite active trading.

Friday, 27 February 2026: Mildly Bearish Momentum Shift and Weekly Close

The week concluded with Concord Biotech gaining 2.31% to close at Rs.1,246.95, marking the week’s high. Technical momentum shifted from strongly bearish to mildly bearish, with MACD and Bollinger Bands indicating some easing of selling pressure. The On-Balance Volume indicator was bullish on weekly and monthly charts, suggesting possible accumulation. However, the stock remained below key long-term moving averages, and the Relative Strength Index showed neutral readings. The Mojo Score was upgraded slightly to 34.0 with a Sell rating, reflecting cautious optimism. Despite the weekly gain of 11.13%, the stock’s year-to-date and one-year returns remain negative, highlighting ongoing challenges.

Daily Price Performance: Concord Biotech Ltd vs Sensex

Key Takeaways

Positive Signals: The stock’s 11.13% weekly gain and intraday rallies on 25 February demonstrated strong short-term buying interest and liquidity, supported by heavy volume and institutional delivery spikes. The mild easing of bearish momentum on 27 February and bullish volume indicators suggest potential base formation.

Cautionary Signals: Despite short-term strength, Concord Biotech remains below key long-term moving averages with a high price-to-book ratio around 6.1-6.3, reflecting expensive valuation amid declining profitability. The downgrade to Strong Sell by MarketsMOJO and persistent negative quarterly earnings trends highlight fundamental weaknesses. The stock’s year-to-date and one-year returns remain deeply negative, underscoring ongoing challenges.

Market Context: Concord Biotech’s performance diverged sharply from the Sensex, which declined 0.96% over the week. The Pharmaceuticals & Biotechnology sector showed mixed trends, with mega-cap stocks outperforming. Concord’s mid-cap status and concentrated promoter ownership provide stability but have not shielded it from sector-specific headwinds and valuation pressures.

Conclusion

Concord Biotech Ltd’s week was characterised by significant volatility, with the stock hitting fresh 52-week lows early in the week before staging a notable rebound to close with an 11.13% gain. The strong intraday rallies and heavy trading volumes indicate active market interest, yet the underlying fundamentals remain challenged by declining profits and expensive valuations. The recent downgrade to a Strong Sell rating by MarketsMOJO reflects these concerns, even as technical momentum shows tentative signs of easing. Investors should remain cautious, balancing the short-term price strength against persistent fundamental and sectoral headwinds. Continued monitoring of technical indicators, volume trends, and upcoming financial results will be essential to assess whether Concord Biotech can sustain its recovery or remains vulnerable to further downside.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →